Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study

References

• Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386:743-800
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Cooper C, Arden N, et al. Health economics in the field of osteoarthritis: an expert’s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2013;43:303-13
   PubMed Web of Science ®Google Scholar
• Dimitroulas T, Duarte RV, Behura A, et al. Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment. Semin Arthritis Rheum 2014;44:145-54
   PubMed Web of Science ®Google Scholar
• Lluch Girbés E, Nijs J, Torres-Cueco R, et al. Pain treatment for patients with osteoarthritis and central sensitization. Phys Ther 2013;93:842-51
   PubMed Web of Science ®Google Scholar
• Lluch E, Torres R, Nijs J, et al. Evidence for central sensitization in patients with osteoarthritis pain: a systematic literature review. Eur J Pain 2014;18:1367-75
   PubMed Web of Science ®Google Scholar
• Arendt-Nielsen L, Nie H, Laursen MB, et al. Sensitization in patients with painful knee osteoarthritis. Pain 2010;149:573-81
   PubMed Web of Science ®Google Scholar
• Hochman JR, French MR, Bermingham SL, et al. The nerve of osteoarthritis pain. Arthritis Care Res 2010;62:1019-23
   PubMed Web of Science ®Google Scholar
• Hochman JR, Davis AM, Elkayam J, et al. Neuropathic pain symptoms on the modified painDETECT correlate with signs of central sensitization in knee osteoarthritis. Osteoarthritis Cartilage 2013;21:1236-42
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kögel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs 2014;28:319-29
   PubMed Web of Science ®Google Scholar
• Baron R, Eberhart L, Kern KU, et al. Tapentadol prolonged release for chronic pain—a review of clinical trials and five years of routine clinical practice data. Pain Practice 2016;Sept 9 Epub ahead of print. DOI:10.1111/papr.12515
   Web of Science ®Google Scholar
• Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee. Clin Drug Investig 2010;30:489-505
   PubMed Web of Science ®Google Scholar
• Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Practice 2010;10:416-27
   PubMed Web of Science ®Google Scholar
• Steigerwald I, Müller M, Kujawa J, et al. Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study. J Pain Res 2012;5:121-38
   PubMedGoogle Scholar
• Steigerwald I, Schenk M, Lahne U, et al. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. Clin Drug Investig 2013;33:607-19
   PubMed Web of Science ®Google Scholar
• Buynak R, Rappaport SA, Rod K, et al. Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial. Clin Ther 2015;37:2420-38
   PubMed Web of Science ®Google Scholar
• Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010;27:381-99
   PubMed Web of Science ®Google Scholar
• Etropolski M, Lange B, Goldberg J, et al. A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain. J Opioid Manage 2013;95:343-56
   Google Scholar
• Etropolski M, Kuperwasser B, Flügel M, et al. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials. Adv Ther 2014;31:604-20
   PubMed Web of Science ®Google Scholar
• Biondi DM, Xiang J, Häufel T, et al. Tolerability and efficacy of tapentadol extended release in elderly patients ≥75 years of age with chronic osteoarthritis knee or low back pain. J Opioid Manage 2015;11:393-403
   PubMedGoogle Scholar
• Sánchez del Águila MJ, Schenk M, Kern K-U, et al. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. Clin Ther 2015;37:94-113
   PubMed Web of Science ®Google Scholar
• Riemsma R, Forbes C, Harker J, et al. Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin 2011;27:1907-30
   PubMed Web of Science ®Google Scholar
• Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician 2013;16:27-40
   PubMed Web of Science ®Google Scholar
• Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol HCl. Drugs Future 2006;31:1053-61
   Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kögel B, et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. JPET 2007;323:265-76
   PubMed Web of Science ®Google Scholar
• OxyContin prolonged release tablets. https://www.medicines.org.uk/emc/medicine/29384. Accessed March 22, 2016
   Google Scholar
• Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for pschopharmacology (DHEW Publication no. ADM 76-338). Washington, DC: US Government Printing Office; 1976
   Google Scholar
• The EuroQoL Group. EuroQoL—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
   PubMed Web of Science ®Google Scholar
• Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA project. J Clin Epidemiol 1998;51:1171-8
   PubMed Web of Science ®Google Scholar
• Slappendel R, Simpson K, Dubois D, et al. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain 2006;10:209-17
   PubMed Web of Science ®Google Scholar
• Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003;35:253-9
   PubMed Web of Science ®Google Scholar